The mean count of copy number alterations in prostate cancers was reported to be 3-fold higher among germline carriers of BRCA2 PSV relative to non-carriers, with gains considerably more common in the region encompassing c-MYC13. This evidence concerns the gene BRCA2 and prostate carcinoma.